At the news
? MIXEDIMPACT 6/10 8-K filed Apr 20, 2026 at 07:15 ET
Passage Bio disclosed updated interim data from its Phase 1/2 upliFT-D trial for PBFT02, showing reduced brain atrophy and stabilized plasma neurofilament levels in FTD-GRN patients. The FDA indicated a randomized controlled trial is required for registration, leading the company to evaluate strategic alternatives to maximize shareholder value.
- PBFT02-treated patients with CDR score 1 showed 64% reduction in whole brain atrophy and 54% reduction in frontotemporal cortex atrophy compared to natural history
- Plasma NfL levels among PBFT02-treated patients showed average reduction of 1.0 pg/mL at 12 months
- FDA indicated a randomized controlled registrational study design is required for PBFT02 in FTD-GRN indication
- Company has initiated a review of strategic alternatives including merger, acquisition, or sale of assets
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access